CGEM

Friendship ended with BYND now CGEM is beat frien

Lynx1 Capital Management LP, a ten percent owner of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), reported purchasing shares of the company’s common stock in a series of transactions totaling $2,103,912. The purchases occurred between October 14 and October 17, 2025. The transactions come as InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $21 and $34. According to a Form 4 filing with the Securities and Exchange Commission, Lynx1 Capital Management acquired 15,032 shares on October 14 at prices ranging from $7.50 to $7.68, for a total of $114,053. On October 15, the firm bought 51,500 shares at prices between $7.88 and $8.00, worth $408,999. This was followed by the purchase of 150,000 shares on October 16, at prices ranging from $8.68 to $9.22, for a total of $1,328,250. The final transaction on October 17 involved the acquisition of 32,217 shares at prices between $7.78 and $7.85, for a total of $252,610. The company maintains a strong financial position with a current ratio of 9.83 and minimal debt. InvestingPro data reveals 8 additional key financial metrics and insights available for subscribers. Following these transactions, Lynx1 Capital Management LP directly holds 8,797,833 shares of Cullinan Therapeutics, representing a significant portion of the company’s $498.59 million market capitalization. Weston Nichols, as sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Lynx1 Capital Management LP, a ten percent owner of Cullinan Therapeutics, Inc. (NASDAQ:CGEM), reported purchasing shares of the company’s common stock in a series of transactions totaling $2,103,912. The purchases occurred between October 14 and October 17, 2025. The transactions come as InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets between $21 and $34. According to a Form 4 filing with the Securities and Exchange Commission, Lynx1 Capital Management acquired 15,032 shares on October 14 at prices ranging from $7.50 to $7.68, for a total of $114,053. On October 15, the firm bought 51,500 shares at prices between $7.88 and $8.00, worth $408,999. This was followed by the purchase of 150,000 shares on October 16, at prices ranging from $8.68 to $9.22, for a total of $1,328,250. The final transaction on October 17 involved the acquisition of 32,217 shares at prices between $7.78 and $7.85, for a total of $252,610. The company maintains a strong financial position with a current ratio of 9.83 and minimal debt. InvestingPro data reveals 8 additional key financial metrics and insights available for subscribers. Following these transactions, Lynx1 Capital Management LP directly holds 8,797,833 shares of Cullinan Therapeutics, representing a significant portion of the company’s $498.59 million market capitalization. Weston Nichols, as sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Thoughts on cgem stock

Thoughts on cgem

Thoughts on cgem stock

Thoughts on cgem?